(Q41907710)

English

Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir

scientific article published on 11 November 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir (English)

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

Kristi L Berger

1

object named as

Kristi L Berger

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

4

object named as

Martin Marquis

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

11

object named as

George Kukolj

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

author name string

Ibtissem Triki

2

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Mireille Cartier

3

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Marie-Josée Massariol

5

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Wulf O Böcher

6

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Yakov Datsenko

7

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Gerhard Steinmann

8

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Joseph Scherer

9

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Jerry O Stern

10

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

language of work or name

0 references

publication date

11 November 2013

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

58

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

2

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

698-705

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

5 June 2018

Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

5 June 2018

Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

5 June 2018

Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

5 June 2018

The role of resistance in HCV treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

5 June 2018

Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

5 June 2018

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

5 June 2018

HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

5 June 2018

Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

5 June 2018

In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

5 June 2018

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

5 June 2018

Hepatitis C virus resistance to protease inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

5 June 2018

Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease Inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

5 June 2018

Evidence for separation of HCV subtype 1a into two distinct clades.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

5 June 2018

In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

5 June 2018

Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

18 August 2018

The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

18 August 2018

Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

18 August 2018

Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

18 August 2018

Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

18 August 2018

NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

18 August 2018

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

18 August 2018

Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910880

18 August 2018

Identifiers

10.1128/AAC.01976-13

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

release_cnlqa4kclffsfmnnciy4zjpeuu

1 reference

https://api.fatcat.wiki/v0/release/cnlqa4kclffsfmnnciy4zjpeuu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41907710&oldid=1929679740"